Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Heuser

Showing results (211-220 of 280) with videos related to

Pageof 28
Sort By:
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Neoplasia|June 2, 2025
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trialUlrich Dührsen, Andreas Bockisch, Bernd Hertenstein, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Nature Communications|March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trialSonja Loges, Michael Heuser, Jörg Chromik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid LeukemiaRaj Bhayadia, Kathrin Krowiorz, Nadine Haetscher, et al.
Leukemia|August 30, 2019
Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)Mridul Agrawal, Peggy Schwarz, Benedetto Daniele Giaimo, et al.
Experimental Hematology|July 13, 2015
MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemiaBernhard Gentner, Nicole Pochert, Arefeh Rouhi, et al.
Blood Advances|June 25, 2026
Rapid and Reproducible Karyotyping with Long Read Sequencing in AML PatientsMichael Heuser, Anna Dolnik, Isabell Arnhardt, et al.
Pageof 28

Showing results (211-220 of 280) with videos related to

Sort By:
Pageof 28
Leukemia|August 3, 2022
Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trialNikolaus Jahn, Ekaterina Jahn, Maral Saadati, et al.
Blood Neoplasia|June 2, 2025
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma: 10-year follow-up of the PETAL trialUlrich Dührsen, Andreas Bockisch, Bernd Hertenstein, et al.
Leukemia|March 24, 2020
Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 studyPau Montesinos, Gail J Roboz, Claude-Eric Bulabois, et al.
Haematologica|December 9, 2017
Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemiaEdith Schneider, Anna Staffas, Linda Röhner, et al.
Hemasphere|July 16, 2024
Refinement of the prognostic impact of somatic <i>CEBPA</i> bZIP domain mutations in acute myeloid leukemia: Results of the AML Study Group (AMLSG)Frank G Rücker, Andrea Corbacioglu, Julia Krzykalla, et al.
Nature Communications|March 24, 2025
Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trialSonja Loges, Michael Heuser, Jörg Chromik, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2018
Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid LeukemiaRaj Bhayadia, Kathrin Krowiorz, Nadine Haetscher, et al.
Leukemia|August 30, 2019
Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML)Mridul Agrawal, Peggy Schwarz, Benedetto Daniele Giaimo, et al.
Experimental Hematology|July 13, 2015
MicroRNA-223 dose levels fine tune proliferation and differentiation in human cord blood progenitors and acute myeloid leukemiaBernhard Gentner, Nicole Pochert, Arefeh Rouhi, et al.
Blood Advances|June 25, 2026
Rapid and Reproducible Karyotyping with Long Read Sequencing in AML PatientsMichael Heuser, Anna Dolnik, Isabell Arnhardt, et al.
Pageof 28